Dr. Karim Fizazi is a medical oncologist, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France and Professor in Oncology at the University of Paris. Dr. Fizazi received his medical degree in 1995 and completed a fellowship in 1997, both in medical oncology. He obtained a PhD in Molecular Oncology in 2003.
Dr. Fizazi has been involved in many Phase I, II and III clinical trials as a national or global coordinating investigator. These include GETUG 12 (a 400 patient national Phase III trial testing docetaxel in high-risk localized prostate cancer), GETUG 13 (an international trial in poor-prognosis non-seminomatous germ-cell tumors), and numerous industry-sponsored clinical trials, including the denosumab versus zoledronic acid pivotal study, the TAK700 post-docetaxel and the cabazitaxel-OGX-011 large Phase III trials in castrate-resistant prostate cancer, and the abiraterone Latitude Phase III trial in patients with hormone-naïve metastatic prostate cancer. He also coordinated the Peace-1 Phase III trial testing the role of abiraterone acetate and that of radiotherapy directed to the prostate in patients with newly diagnosed metastatic prostate cancer treated with ADT, and the Peace-2 Phase III trial testing cabazitaxel and pelvic lymph node irradiation in patients with high-risk localized prostate cancer treated with ADT-radiotherapy.